Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY) dataset
| Field | Value | Language |
| dc.contributor.author | Jardine, Meg | |
| dc.date.accessioned | 2024-02-22T21:58:18Z | |
| dc.date.available | 2024-02-22T21:58:18Z | |
| dc.date.issued | 2024-02-23 | |
| dc.identifier.uri | https://hdl.handle.net/2123/32242 | |
| dc.description.abstract | This dataset includes up to 787 participants receiving an oral angiotensin receptor blocker (no placebo per standard of care in Australia, and telmisartan in India) recruited from seventeen hospitals in India and Australia. Baseline data includes demographics (age, sex, ethnicity, height, and weight), pregnancy status, smoking status, and co-morbidities. Primary follow-up data was collected daily from days 1 to 28 during treatment period and will include clinical outcome (Clinical Health Score), temperature, respiratory measures (oxygen saturation, use of supplemental oxygen), hypotension (vasopressor requirement), incidence of acute kidney injury, and hyperkalaemia (serum potassium concentration of >6.0 mmol/L). | en_AU |
| dc.rights | Other | en_AU |
| dc.title | Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease (CLARITY) dataset | en_AU |
| dc.type | Dataset | en_AU |
| dc.identifier.doi | 10.25910/ghrw-5k88 | |
| dc.rights.other | Access can be requested via the Health Data Australia catalogue (https://researchdata.edu.au/health). A copy of the Data Sharing Guidelines can be found in https://rb.gy/bgrcq. For further information please contact the Health Studies Australian National Data Asset (HeSANDA) SHP-CTC node ([email protected]). | en_AU |
| usyd.faculty | SeS faculties schools::Faculty of Medicine and Health::NHMRC Clinical Trials Centre | en_AU |
| workflow.metadata.only | Yes | en_AU |
Associated file/s
Associated collections